444 Presence of AR-V7 splice variant or AR C terminal loss in the CTCs of mCRPC patients identifies patients with improved PSA response with taxanes over androgen receptor signaling directed therapies (ARS Rx). (September 2015) - Scher, H.I.; Kelvin, J.; Lu, D.; Louw, J.; Packer, D.; Bambury, R.; Rathkopf, D.; Schreiber, N.; Brennan, R.; Prigozhina, N.; Brown, D.; Jendrisak, A.; et al.